Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.
Quote | Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Last: | $84.79 |
---|---|
Change Percent: | 0.0% |
Open: | $84.85 |
Close: | $84.79 |
High: | $85.61 |
Low: | $84.04 |
Volume: | 115,722 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
Message Board Posts | Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Subject | By | Source | When |
---|---|---|---|
When next dividends for CVRs? July? January? :-D | S-BEES-BUMBLEBEE | investorshub | 04/26/2023 11:40:10 AM |
any good news ? | Erz | investorshub | 04/25/2023 10:54:07 AM |
You're welcome! | S-BEES-BUMBLEBEE | investorshub | 12/25/2022 11:23:44 AM |
Danke sehr ! | Erz | investorshub | 11/11/2022 8:46:36 AM |
"(..) In connection with our acquisition of Metabasis | S-BEES-BUMBLEBEE | investorshub | 11/10/2022 8:32:13 PM |
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...